Foresight Capital's model of investing across early, middle, and late stages from one fund provides a unique advantage. Their understanding of late-stage market needs and challenges directly informs and improves their selection process for early-stage companies, creating a powerful feedback loop that specialized VCs lack.

BridgeBio's founder saw biotech VCs exclusively funding high-risk "home run" platforms. He built a company to acquire therapies for smaller rare genetic diseases—"singles and doubles"—that were ignored. Aggregating these de-risks the portfolio and creates a major market opportunity.

An investment from the nonprofit Beyond Celiac provides more than capital; it offers powerful third-party validation for a novel therapeutic target. For investors and potential pharma partners, this endorsement from a patient organization helps de-risk a new technology and demonstrates a clear patient need and interest.

Yosemite provides unrestricted grants to academic scientists, de-risking novel research and building relationships. This early support creates a unique deal flow engine, leading to investment opportunities in companies that later spin out from this foundational work.

AAVantgarde's foundational science originated from the Italian charity Teleton. This provided decades of grant-funded research and de-risked technology, showcasing a powerful, non-traditional model for biotech incubation outside of typical VC or academic spin-out routes, culminating in Teleton achieving the first-ever BLA approval for a charity.

Early-stage biotech companies struggle to navigate clinical development for autoimmune diseases. Disease-specific foundations hold crucial insights on patient subsets, recruitment, and key opinion leaders, yet the interface between VCs and these foundations is often inefficient and difficult to navigate, leading to missed opportunities and flawed trial execution.

CZI focuses on creating new tools for science, a 10-15 year process that's often underfunded. Instead of just giving grants, they build and operate their own institutes, physically co-locating scientists and engineers to accelerate breakthroughs in areas traditional funding misses.

Renowned gene therapy pioneer Jim Wilson was forced to spin out ultra-rare disease programs into a new company after his initial venture failed to attract VC funding. This demonstrates that even elite scientific leadership cannot overcome investor disinterest in this segment without powerful, predictable government incentives like transferable priority review vouchers.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.